Allogene Therapeutics Announces CFO Geoffrey Parker to Retire Nov 6, 2026

What Happened
Allogene Therapeutics filed a Form 8-K (Item 5.02) reporting that Geoffrey Parker, the company's Executive Vice President and Chief Financial Officer and principal financial officer, provided notice of his retirement on August 31, 2026. His retirement is effective November 6, 2026.

Key Details

• Notice of retirement was provided on August 31, 2026.
• Retirement effective date: November 6, 2026.
• Mr. Parker served as Executive Vice President and Chief Financial Officer and was the company’s principal financial officer.
• The 8-K does not identify a successor or provide transition details.

Why It Matters
A CFO departure is a material leadership change that can affect financial strategy, reporting continuity, and investor confidence. Investors should monitor Allogene for follow-up disclosures naming an interim or permanent successor and any commentary on transition plans or potential impacts on financial operations. This 8-K is the company’s official notice of the change.